Kornimate/medical-research-clean huggingface dataset:
risk factors associated with recurrence and life-threatening complications for csoj

Conditions: Suppurative Osteomyelitis of Jaw; Potential Abnormality of Glucose Tolerance

Summary: clinically, recurrence and life-threatening complications are challenging problems for chronic suppurative osteomyelitis of the jaw. there is no quantitative analysis or report about the causes of or risk factors for the two problems. doctors identify the causes or risk factors only through clinical experience. the investigators performed a retrospective study of 322 patients with chronic suppurative osteomyelitis of the jaw. the risk factors for the above mentioned two problems were analyzed by logistic regression analysis. the investigators found that some of the patients' general conditions, including age, admission temperature, admission white blood cell count, pre-admission antibiotic administration without consultation, location of the lesion, and general patient condition, were the risk factors. the results indicate that doctors should be mindful of those risk factors and that the management should be more aggressive when the above risk factors are present.

this is a retrospective study of 322 patients hospitalized with csoj. the socio-demographic and clinical characteristics were recorded. the risk factors for the above two problems were analyzed by logistic regression analysis. frequency and percentage were used to indicate descriptive research factors. a univariate logistic regression analysis was performed to calculate the odds ratio (or) and to identify preliminary risk factors. the preliminary risk factors were further identified by multivariate logistic regression analysis.

Eligibility criteria:
inclusion criteria: * the diagnosis on admission was made on the basis of the presence of sequestra and laminations of periosteal new bone in the pathological area. * the other diagnostic criteria is that symptoms such as local pain, pyorrhea, fever, swelling, fistula, neuropalsy, odontoseisis, lymphadenopathy, bromopnea, and trismus pain are unresponsive or insensitive to conservative therapy and simple debridement. exclusion criteria: * patients without confirmed evidence of csoj and (or) without standard treatment (a combination of antimicrobial therapy and surgery consisting of incision and drainage, debridement or sequestrectomy) were excluded. * paget's disease, hypercementosis, fibrous dysplasia, and early stage malignant bone tumor were differentially diagnosed and excluded.

Keywords: csoj recurrence life-threatening complications risk factors
flagyl microbiome in crohn's disease

Conditions: Crohn Disease

Summary: this study will compare the types of bacteria in the colon before and after colon resection surgery. the investigator will also compare standard post-operative antibiotic treatment to flagyl (metronidazole) treatment post-operatively to see if giving the antibiotic, decreases the incidence of return of crohn's disease.

participants who are scheduled for colon resection for crohn's disease will be invited to take part in this randomized study. participants will be randomized 1:1 to either metronidazole 250 mg three times a day, starting after surgery, for three months, or the local usual standard of care after surgery, which may be a different antibiotic prescribed by the physician. participants will also provide a stool sample at the following time points: prior to surgery, the day of discharge, at their follow-up appointment (usually about two weeks after surgery), three months, and six months. participants will also be followed to determine their clinical outcome.

Eligibility criteria:
inclusion criteria: * 20-80 years old who is deemed an acceptable surgical candidate for ileocolic resection. exclusion criteria: * any patients that are dependent on total parenteral nutrition and unable to tolerate oral intake * patients who will undergo resection but will have an ileostomy created * patients on maintenance antibiotics for their disease
validation study for endometriosis pro

Conditions: Endometriosis

Summary: assess the psychometric properties of the endometriosis symptom diary (esd) and the endometriosis impact scale (eis) and provide evidence whether the pro measures are reliable, valid and able to detect changes over time in approximately 250 patients with mild, moderate or severe endometriosis confirmed by laparoscopy.


Eligibility criteria:
inclusion criteria: * women with endometriosis confirmed by laparoscopy or laparotomy within five years before the baseline visit * good general health (except for findings related to endometriosis) as proven by medical history * patient has experienced endometriosis symptoms (i.e. pain) in the past 4 weeks, as assessed by a numerical rating scale (nrs) exclusion criteria: * any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results * undiagnosed abnormal genital bleeding * abuse of alcohol, drugs, or medicine (e.g., laxatives) * simultaneous participation in another clinical trial. participation in another clinical trial prior to study entry that might have an impact on the study objectives, at the discretion of the investigator. * major surgery scheduled for the study period, except therapeutic surgical procedure for endometriosis * close affiliation with the study site; e.g. a close relative of the investigator, dependent person (e.g. employee or student of study site) * inability to cooperate with the study procedures for any reason, including the following examples: language comprehension, psychiatric illness, inability to get to the study site * previous enrollment to this study * regular use of pain medication due to other underlying diseases * known pregnancy

Keywords: endometriosis, validation study
reduction of radiation dose and contrast use during cryoballoon pulmonary vein isolation

Conditions: Atrial Fibrillation

Summary: this is a multi-site, randomized, investigator-initiated pilot study to evaluate the efficacy of investigational techniques to reduce fluoroscopy time or radiation dose and the amount of radio opaque contrast used during a cryoballoon pulmonary vein isolation procedure for atrial fibrillation. one group of subjects will have the procedure performed with intracardiac echo maneuvers to assess cryoballoon occlusion of the pulmonary vein and will be compared to a group of subjects who will receive the standard medical treatment with fluoroscopy and angiography.

surgical and catheter based technologies target triggers that initiate atrial fibrillation located in the pulmonary veins (pv). in order to isolate these triggers, radiofrequency energy or freezing is used to destroy the atrial tissue which propagate electrical impulses into and out of the pulmonary veins (pv), to achieve pulmonary vein isolation (pvi). use of a patented cryoballoon catheter (medtronic) to perform pvi has been shown to be safe and efficacious under fluoroscopic guidance with contrast angiography. the objective of this study is to identify methods to reduce radiation dose and radio opaque contrast use while maintaining pvi efficacy and safety.

Eligibility criteria:
inclusion criteria: * paroxysmal atrial fibrillation refractory to treatment with anti-arrhythmic drugs * must be able to undergo pre-operative cardiac ct angiogram or cardiac mri to define pulmonary vein anatomy. exclusion criteria: * planned use of radiofrequency cardiac ablation * presence of a cardiac implantable electronic device * conditions where manipulation of the catheter would be unsafe such as intracardiac thrombus * patients with active systemic infections * patients with cryoglobulinemia * pregnant and/or breast-feeding females are excluded from this study.

Keywords: cryoballoon atrial fibrillation pulmonary vein isolation
optimization of assessment and grading for lid wiper epitheliopathy

Conditions: Dry Eye

Summary: the purpose of this study is to assess eyelid margin staining, termed "lid wiper epitheliopathy" (lwe), in three populations. the hypothesis is lwe will be more prevalent in symptomatic contact lens wearers than non-symptomatic contact lens wearers and least prevalent in asymptomatic non-contact lens wearers.


Eligibility criteria:
inclusion criteria: * has full legal capacity to volunteer; * has read and signed an information consent letter; * is willing and able to follow instructions and maintain the appointment schedule; * has had an ocular examination in the last two years; * has clear corneas and no active ocular disease; * other protocol-defined inclusion criteria may apply. exclusion criteria: * has any ocular disease; * has a systemic condition that may affect a study outcome variable; * is using any systemic or topical medications that may affect ocular health; * has known sensitivity to the diagnostic pharmaceuticals to be used in the study; * has undergone corneal refractive surgery; * currently wears contact lenses on an extended wear basis (overnight); * has any clinically significant lid or conjunctival abnormalities, neovascularization, corneal scars or corneal opacities; * other protocol-defined exclusion criteria may apply.

Keywords: eye eyelid contact lenses dry eye disease
comparing the efficacy of continuous and pulsed ultrasound treatments in lateral epicondylitis

Conditions: Lateral Epicondylitis

Summary: objectives: the purpose of this study was to investigate the efficacy of continuous and pulsed ultrasound treatments in lateral epicondylitis and to compare the efficacy of these two treatments against each other and placebo. patients and methods: fifty one patients diagnosed with lateral epicondylitis were included to the study. patients were randomised to continuous ultrasound, pulsed ultrasound and placebo groups by using closed envelop method. first group received continuous ultrasound treatment. second group received pulsed ultrasound treatment in proportion as. third group received of placebo treatment. resting and moving pain levels of the patients were evaluated by using visual analog scale. muscle strength was evaluated by using dynamometer. for functional evaluation duruoz's hand index and patient-rated tennis elbow evaluation (prtee) scales were used. evaluations were made at baseline, at the end of the therapy, and one month after the therapy. in addition, at baseline and at the end of the therapy, the thickness of the common extensor tendon was measured by using ultrasonic imaging (usg).

the purpose of this study was to investigate the efficacy of continuous and pulsed ultrasound treatments in lateral epicondylitis and to compare the efficacy of these two treatments against each other and placebo. fifty one patients (33 women, 18 men) diagnosed with lateral epicondylitis were included to the study. patients were randomised to continuous ultrasound (n=17), pulsed ultrasound (n=17) and placebo (n=17) groups by using closed envelop method. first group received 10 sessions of 1 w/cm2 and 1,5 mhz continuous ultrasound treatment. second group received 10 sessions of 1 w/cm2 and 1,5 mhz pulsed ultrasound treatment in proportion as 1:4. third group received 10 sessions of placebo treatment with the same device seemed to be working but without delivering any output. resting and moving pain levels of the patients were evaluated by using visual analog scale. muscle strength was evaluated by using dynamometer. for functional evaluation duruoz's hand index and patient-rated tennis elbow evaluation (prtee) scales were used. evaluations were made at baseline, at the end of the therapy, and one month after the therapy. in addition, at baseline and at the end of the therapy, the thickness of the common extensor tendon was measured by using ultrasonic imaging (usg).

Eligibility criteria:
inclusion criteria: * aged between 18-70 years * pain on the lateral side of the elbow for less than six months * tenderness over the lateral epicondyle * pain during extension of wrist and fingers exclusion criteria: * upper extremity and neck disorders * other elbow pathologies * presence of tendon rupture * usage of non-steroidal anti inflammatory drugs * joint limitations due to a previous radius/ulna fracture * previous elbow surgery * osteoporosis, malignancy, hemophilia, neurologic deficit(s) in the ipsilateral upper limb * cognitive disfunction

Keywords: lateral epicondylitis, therapeutical ultrasound
gemcitabine/oxaliplatin (gemox) with or without erlotinib (tarceva) in advanced biliary tract carcinoma

Conditions: Unresectable, Metastatic Biliary Tract Carcinoma

Summary: the purpose of this study is to determine whether gemcitabine/oxaliplatin (gemox) with or without erlotinib (tarceva) is effective in the treatment of unresectable, metastatic biliary tract carcinoma.

this is a phase iii study of gemcitabine/oxaliplatin (gemox) with or without erlotinib in unresectable, metastatic biliary tract carcinoma.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 2. histologically or cytologically confirmed adenocarcinoma of biliary tract 3. unresectable or metastatic 4. ecog performance status of 0\~2 5. measurable or evaluable lesion per recist criteria 6. adequate marrow, hepatic, renal and cardiac functions 7. no prior chemotherapy or molecularly targeted therapy for the advanced biliary carcinoma (prior adjuvant chemotherapy will be allowed if administered ≥ 6 months from the study entry) 8. provision of a signed written informed consent exclusion criteria: 1. severe co-morbid illness and/or active infections 2. pregnant or lactating women 3. active cns metastases not controllable with radiotherapy or corticosteroids 4. known history of hypersensitivity to study drugs 5. prior exposure to egfr tyrosine kinase inhibitor

Keywords: unresectable, metastatic biliary tract carcinoma gemcitabine/oxaliplatin (gemox) erlotinib
diagnostic and prognostic accuracy of gold nanoparticles in salivary gland tumours

Conditions: Carcinoma Ex Pleomorphic Adenoma of Salivary Glands; Pleomorphic Adenoma of Salivary Glands

Summary: nano-based diagnostic tool can provide promising highly sensitive, specific biomarker for early detection and treatment of salivary gland tumours compared to non-conjugated biomarkers and in turn improves patient prognosis and outcome.

cancer stem cells form a small subset of highly tumorigenic cells within the bulk of the tumours which mainly responsible for initiation, invasion, rapid growth, metastasis and therapeutic resistance in different types of human cancers. nowadays, nanotechnology has increasing attention in multi-disciplinary research fields. conjugated gold nanoparticles are widely used as biomarkers and bio-delivery vehicles in the medicine as well as early and advanced cancer detection and treatment. the current work aimed to introduce a novel diagnostic and prognostic approach in early detection of cancer stem cells in salivary gland tumours using gold nanoparticles conjugated to cd24 (cd24-gold nanocomposite).

Eligibility criteria:
inclusion criteria: * benign pa of major and minor salivary glands (pa group), * cxpa of major and minor salivary glands (cxpa group). * border of excision biopsy of mucocele in the lip mucosa of healthy individuals used as normal controls (control group). * surgical excision of tumors with no preoperative chemotherapy or radiotherapy. for parotid tumours partial or total parotidectomy, surgery was performed with or without facial nerve preservation and the later was carried out commonly when the nerve was involved by tumour. for tumours in the other glands, complete surgical excision with the involved gland and the suspicious adjacent structures was performed. exclusion criteria: * all epithelial origin salivary gland tumours other than pa and cxpa. * all mesenchymal origin salivary gland tumours. * all inflammatory and cystic lesions of salivary glands. * metastasis in salivary glands. * patients received preoperative chemotherapy or radiotherapy.

Keywords: cancer stem cells cd24-gold nanocomposite cd24 gold nanoparticles sensitivity specificity
improvement of low back pain after decompression in patients with degenerative spinal canal stenosis

Conditions: Low Back Pain; Lumbar Spinal Stenosis

Summary: degenerative lumbar spine disease is a leading cause of disability in the world; it encompasses conditions such as spondylolisthesis, disc degeneration, and lumbar spinal stenosis. those conditions present with a variety of clinical symptoms, including lower extremity pain, weakness, and low back pain (lbp) of varying levels of severity and in severe cases urine and stool incontinence may result.

degenerative lumbar spine disease is a common indication for lumbar decompression surgery, especially in elderly patients. moreover, clinical studies prove that decompression is superior to conservative treatment with more favorable outcomes . surgical options for decompressing the lumbar spine vary from minimally invasive disc decompression to open laminectomy and foraminotomy. the surgery aims to improve the quality of life in appropriately selected patients , in the form of improvement of walking distance, lower limbs pain, and other symptoms of spinal compression. few papers assessed lbp improvement after lumbar decompression surgery . the common practice that patients with degenerative canal stenosis and low back pain should undergo fusion surgery is not evidence based. in this study the investigators aim to assess the improvement of clinical symptoms, especially low back pain and lower limbs pain in patients with degenerative lumbar spine disease after undergoing lumbar decompression surgery.

Eligibility criteria:
inclusion criteria: 1. patients with degenerative lumbar spine disease admitted to assiut university hospitals, department of orthopaedic and trauma surgery between march 2023 and march 2024, to whom lumbar decompression surgery is indicated regardless of age or neurological symptoms. 2. patients with grade one spondylolisthesis without evident instability can be added. exclusion criteria: 1. patients who are not available for follow up 2. patients who refuse to participate in the study 3. patients with evidence of instability 4. previously operated patients on the same or adjacent segment.
long-term tetrahydrobiopterin treatment in pku patients of 0-18 years - study on phenylalanine tolerance and safety

Conditions: Phenylalanine Hydroxylase Deficiencies

Summary: the aim of the study is to confirm the efficacy and safety of bh4 in the treatment of hyperphenylalaninemia caused by phenylalanine hydroxylase deficiency in patients responsive to bh4. the primary objective is to assess the effect of bh4 on phenylalanine tolerance compared to placebo under optimal blood phenylalanine control and to demonstrate safety in 12 months long-term treatment. additionally population pk will be assessed.


Eligibility criteria:
inclusion criteria: * female and male patients, aged 0-18 years * phenylalanine-4-hydroxylase (pah) deficiency shown by mutation analysis * blood phenylalanine concentration in the target range under dietary treatment * written consent of a parent or legal representative * assumed availability within the period of study participation * patients/parents willing and able to follow the recommended diet * use of an effective method of contraception in female patients of child bearing potential exclusion criteria: * bh4-deficiency due to genetic disorders in biosynthesis or recycling of bh4 * history or current evidence of poor diet compliance * history or current evidence of clinically relevant allergic or idiosyncratic reactions to drugs or food * history of allergic reactions to bh4 or its excipients * positive pregnancy test (ß-hcg in serum) and lactating females * participation in other drug trials within the last 30 days before start for the study

Keywords: phenylketonuria phenylalanine hydroxylase deficiency bh4 responsive tetrahydrobiopterin newborns infants children adolescents
intraoperative brain microdialysis to assess neuroinflammation in epileptic tissue immediately prior to surgical resection.

Conditions: Epilepsy

Summary: this research study will investigate the fluid from the area of the brain that is being removed during clinical epilepsy surgery. the goal is to analyze this fluid for inflammatory markers that can potentially help identify new strategies in the future to control seizures in individuals with epilepsy who fail to respond to currently available drugs.


Eligibility criteria:
inclusion criteria * failure to respond to at least two trials of anti-seizure drugs with different mechanisms of action * normal mri exclusion criteria * active immunomodulatory therapy * autoimmune disorder * signs or symptoms consistent with comorbid infection * oncological comorbidity
ibuprofen 5% topical gel cipt

Conditions: Pain

Summary: this study will determine the potential of ibuprofen 5% topical gel and its vehicle gel to cause irritation after repeated topical application to the healthy skin of human subjects under controlled conditions.


Eligibility criteria:
inclusion criteria: healthy male and/or female subjects (to be confirmed by medical history) 18 years of age or older, female subjects of childbearing potential and males who are using an acceptable form of birth control, subjects who are free of any systemic or dermatologic disorder exclusion criteria: have skin disease at the application site, not willing to stop use of systemic or topical analgesics, corticosteroids, or antihistamines, unwilling or unable to stop use of sunscreens, creams, or similar products on the back during the study

Keywords: cumulative irritancy patch test (cipt)
darunavir levels, virological efficacy, proviral adn and resistances in patients on darunavir/ritonavir monotherapy

Conditions: HIV-infection

Summary: to evaluate the relationship between plasma and intracellular darunavir (drv) concentrations and virological efficacy in hiv-infected patients on drv/rtv monotherapy.

to be enrolled, subjects had a plasma hiv-rna \<50 copies/ml for at least 6 months based, virologic failure while on a pi-containing regimen was allowed if the genotypic resistance tests showed no major resistance mutation associated to reduced susceptibility to drv/rtv according to the international aids society. patients with transitory episodes of detectable plasma hiv-rna viral load ("blip") preceded and followed by a plasma viral load \<50 copies/ml without changes in antiretroviral treatment could also been included. the only exclusion criteria were pregnancy, hepatitis b coinfection and the concomitant use of drugs with potential major interactions with drv/rtv pharmacokinetics.

Eligibility criteria:
inclusion criteria: * older than 18 years, starting an antiretroviral regimen based on darunavir-ritonavir (800/100 mg) once daily monotherapy between june 2010 and september 2010 * plasma rna-vih \< 50 copies/ml on stable antiretroviral treatment for ≥ 6 months * absence of resistance mutations in the protease gene, based on treatment history and/or genotypic resistance testing. that would decrease darunavir susceptibility exclusion criteria: * pregnancy * chronic b hepatitis * genotypic resistance tests with evidence of resistance mutations in the protease gene that would decrease darunavir susceptibility * concomitant use of drugs with potentially adverse interactions with darunavir-ritonavir pharmacokinetics, such as rifampin

Keywords: antiretroviral therapy boosted-darunavir monotherapy resistance proviral dna-hiv